Clinical Significance of Early Venous Filling Detected Via Preoperative Angiography in Glioblastoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Aug 12

PMID 37568616

Authors

Kotaro Tatebayashi

Noriyuki Nakayama

Daisuke Sakamoto

Tomoko Iida

Shun Ono

Ikuo Matsuda

Yukiko Enomoto

Michihiro Tanaka

Mitsugu Fujita

Seiichi Hirota

Shinichi Yoshimura

Affiliations

Soon will be listed here.

Abstract

Preoperative angiography in glioblastoma (GBM) often shows arteriovenous shunts and early venous filling (EVF). Here, we investigated the clinical implications of EVF in GBM as a prognostic and vascular mimicry biomarker. In this retrospective multicenter study, we consecutively enrolled patients who underwent angiography with a GBM diagnosis between 1 April 2013 and 31 March 2021. The primary and secondary endpoints were the differences in overall survival (OS) and progression-free survival (PFS), respectively, between cases with and without EVF. Of the 133 initially enrolled patients, 91 newly diagnosed with GBM underwent preoperative angiography and became the study population. The 6-year OS and PFS were significantly worse in the EVF than in the non-EVF group. Moreover, 20 GBM cases (10 with EVF and 10 without EVF) were randomly selected and evaluated for histological vascular mimicry. Except for two cases that were difficult to evaluate, the EVF group had a significantly higher frequency of vascular mimicry than the non-EVF group (0/8 vs. 5/10, = 0.04). EVF on preoperative angiography is a robust prognostic biomarker for GBM and may help detect cases with a high frequency of histological vascular mimicry.

Citing Articles

CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review.

Begagic E, Beculic H, duzic N, Dzidic-Krivic A, Pugonja R, Muharemovic A Biomedicines. 2024; 12(1).

PMID: 38275409 PMC: 10813360. DOI: 10.3390/biomedicines12010238.

References

Mei X, Chen Y, Zhang Q, Chen F, Xi S, Long Y . Association between glioblastoma cell-derived vessels and poor prognosis of the patients. Cancer Commun (Lond). 2020; 40(5):211-221. PMC: 7238665. DOI: 10.1002/cac2.12026. View

Yang J, Liao Y, Mai D, Xie P, Qiang Y, Zheng L . Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis. 2016; 19(2):191-200. DOI: 10.1007/s10456-016-9500-2. View

Sahara N, Hartanto R, Yoshuantari N, Dananjoyo K, Widodo I, Malueka R . Diagnostic Accuracy of Immunohistochemistry in Detecting MGMT Methylation Status in Patients with Glioma. Asian Pac J Cancer Prev. 2021; 22(12):3803-3808. PMC: 9080354. DOI: 10.31557/APJCP.2021.22.12.3803. View

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

Fan X, Wang Y, Wang K, Liu S, Liu Y, Ma J . Anatomical specificity of vascular endothelial growth factor expression in glioblastomas: a voxel-based mapping analysis. Neuroradiology. 2015; 58(1):69-75. DOI: 10.1007/s00234-015-1602-9. View

Ohta H, Nakano S, Yokogami K, Iseda T, Yoneyama T, Wakisaka S . Appearance of early venous filling during intra-arterial reperfusion therapy for acute middle cerebral artery occlusion: a predictive sign for hemorrhagic complications. Stroke. 2004; 35(4):893-8. DOI: 10.1161/01.STR.0000119751.92640.7F. View

Maniotis A, Folberg R, Hess A, Seftor E, Gardner L, Peer J . Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999; 155(3):739-52. PMC: 1866899. DOI: 10.1016/S0002-9440(10)65173-5. View

Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M . The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021; 21(1):62. PMC: 7816485. DOI: 10.1186/s12935-020-01719-5. View

Mariani L, Schroth G, Wielepp J, Haldemann A, Seiler R . Intratumoral arteriovenous shunting in malignant gliomas. Neurosurgery. 2001; 48(2):353-7; discussion 357-8. DOI: 10.1097/00006123-200102000-00022. View

10.

Treps L, Faure S, Clere N . Vasculogenic mimicry, a complex and devious process favoring tumorigenesis - Interest in making it a therapeutic target. Pharmacol Ther. 2021; 223:107805. DOI: 10.1016/j.pharmthera.2021.107805. View

11.

Pries A, Hopfner M, le Noble F, Dewhirst M, Secomb T . The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer. 2010; 10(8):587-93. PMC: 3109666. DOI: 10.1038/nrc2895. View

12.

Li J, Wang M, Won M, Shaw E, Coughlin C, Curran Jr W . Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys. 2010; 81(3):623-30. PMC: 3783211. DOI: 10.1016/j.ijrobp.2010.06.012. View

13.

Baumann C, Tichy J, Schaefer J, Steinbach J, Mittelbronn M, Wagner M . Delay in diagnosing patients with right-sided glioblastoma induced by hemispheric-specific clinical presentation. J Neurooncol. 2019; 146(1):63-69. DOI: 10.1007/s11060-019-03335-4. View

14.

FERRIS E, GABRIELE O, HIPONA F, Shapiro J . Early venous filling in cranial angiography. Radiology. 1968; 90(3):553-7. DOI: 10.1148/90.3.553. View

15.

Zlatescu M, TehraniYazdi A, Sasaki H, Megyesi J, Betensky R, Louis D . Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001; 61(18):6713-5. View

16.

Balana C, De Las Penas R, Sepulveda J, Gil-Gil M, Luque R, Gallego O . Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016; 127(3):569-79. DOI: 10.1007/s11060-016-2065-5. View

17.

Li D, Zhang Z, Xia C, Niu C, Zhou W . Non-Coding RNAs in Glioma Microenvironment and Angiogenesis. Front Mol Neurosci. 2021; 14:763610. PMC: 8595242. DOI: 10.3389/fnmol.2021.763610. View

18.

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

19.

Ho R, Ho I . Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade. Cancers (Basel). 2021; 13(15). PMC: 8345045. DOI: 10.3390/cancers13153686. View

20.

Zhang H, Huang Z, Zou X, Liu T . Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016; 7(50):82473-82481. PMC: 5347706. DOI: 10.18632/oncotarget.12666. View